Question-and-Answer Session
Operator
(Operator Instructions) Our first question comes from Steve Brozak - WBB Securities.
Steve Brozak - WBB Securities
I’d like a little bit of comparison with for instance the B12 program as how you see it and how you see the process being much closer to market than what you would normally expect when you see a biotech or specialty pharmaceutical company going through the process.
Michael V. Novinski
I think it’s safe to say that our goals are that there is the potential to bring this technology to a commercial level somewhere toward the second half of next year if everything will go as planned. Now we do have a number of things that have to be done. There are some studies that have to be in place as we talked about in the one slide. We have to look at the lower doses because we looked at relatively high doses but we do have to look at lower doses from a pharmacokinetics standpoint. These studies are not that long but they do have to be thought through and they are being done with the sound expert advice of scientific experts as well as the sound discussions with our Board, and then we want to look at efficacy studies in the fourth quarter. But we do believe that as opposed to a drug pathway that we would have the potential opportunity of trying to bring this to market somewhere toward the latter half of next year. And I think that’s the point that you’re trying to get me to bring out. Is that not correct?
Steve Brozak - WBB Securities
Great. One follow up. It looks like you’ve got events that are staggered that will continue and that can just be added on once you do get this commercial proof of concept. What kind of new interest are you seeing in terms of potential partnership by comparison to when you started up initially?
Michael V. Novinski
I think that one thing I would like to say in answering this question is that I think the understanding of the technology has vastly improved over the last 12 months and this has generated much more interest in positioning the eligen technology in which our goal is as the number one solution when it comes to the absorption of selected molecules. It’s a process where we’ve seen an increased interest. We are having a number of discussions from a preclinical to a clinical and I think this process is just going to continue as we move forward with the goals that we have set in mind. And that is to increase the demand for this technology.
- To read the full transcript on Seeking Alpha, click here »
